We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lombard Med.Tec | LSE:LMT | London | Ordinary Share | GB00B7FT8W85 | ORD 20P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 188.50 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
12/1/2011 20:57 | so i wonder what's going on, not that i am complaining! | webshares | |
12/1/2011 20:17 | SP continuing to climb ...nice...now 124% up on my outlay...wished I'd bought alot more...seems there's tons of potential here! (imho, dyor) | rcktmn | |
12/1/2011 20:03 | wahay. 50% up for me presently and this is potentially is the beginning. i hope no one is tempted to sell. | webshares | |
12/1/2011 19:11 | Hi Rayrac when Aorfix is approved in the US the market for stent grafts could potentially grow from $500m to $600m because Aorfix will be able to treat a group of patients who are untreatable with the devices currently approved. It is estimated the market size of this group is $100m. And of course only Aorfix will be approved for this group of patients with tortuous anatomies and will have this $100m segment exclusively. On top of that Aorfix will also be able to compete very effectively for a slice of the $500m market. This is the true excitement behind LMT and Aorfix - having the only product which can exclusively treat a large group of patients without competitors. | tctmeeting | |
12/1/2011 15:08 | At times like this I always find myself wishing I had nought more! This is defiantely the long game with this one, always has one, however it seems the 'end game' maybe be closer than a lot of people expected - I wasn't expecting this to rocket until at least mid 2011. But yeah, bags of potential, focused on their product, delivered many cost savings, and are well funded up to product launch I believe. Am I topping up at this point - probably not, if I had spare cash without having to sell other investments, yes, probably would. | munkychunky | |
12/1/2011 13:35 | This co is ripe to be swallowed up by a larger player. | restassured | |
12/1/2011 12:15 | Im showing as a sell, but of course, if you look at the trade time, it was a buy. | rayrac | |
12/1/2011 11:55 | Meant $500m john. I'm well aware of what's what with this share, having been here for many years, including the previous incarnation! | rayrac | |
12/1/2011 11:46 | $500 million rayrac not $500 thousand. The US is the largest market for AAA stent grafts, worth over $500 million and we remain confident of achieving approval for Aorfix™ in this important market." | johnyee 7 | |
12/1/2011 11:34 | Could be somethings going to be announced. | philo124 | |
12/1/2011 11:30 | My feelings too jab. I think they mention the US mkt alone is worth $500m and I think they mention double that in world total. | rayrac | |
12/1/2011 11:18 | 1 million buy just went through at 2.04. | johnyee 7 | |
12/1/2011 11:16 | On to 3p and beyond | restassured | |
12/1/2011 11:03 | Over 2p !! | philo124 | |
12/1/2011 10:58 | Rayrac. by the looks of it, someone seems to be hovering up all the stock on this rise, could get exciting here. | jab118 | |
12/1/2011 10:38 | Probably get taken out by J&J, if they think a $500m market is worth it. | rayrac | |
12/1/2011 10:34 | Just bought 10x that on line, just a tester. :) | rayrac | |
12/1/2011 10:29 | 10k?! I doubt it.:) | rayrac | |
12/1/2011 10:21 | is this the rise that all have been waiting for.can only get 10k online. | johnyee 7 | |
12/1/2011 09:50 | The buying this morning is no longer from the shares mag tip,I think we have a little gem here | balcony | |
12/1/2011 09:42 | Nice buys going through. | johnyee 7 | |
11/1/2011 20:04 | There's certainly been a change in investor interest since the RNS on 13 December announcing the filing of the fifth FDA module and the postive update re its 2011 schedule: "We set out clear timelines for submission of the PMA modules required for FDA approval of Aorfix(TM) earlier this year and we remain firmly on track to achieve them. We look forward to submitting the final PMA module demonstrating the clinical evidence for the use of the Aorfix(TM) stent graft in the treatment of complex tortuous anatomy during the first half of 2011. The US is the largest market for AAA stent grafts, worth over $500 million, and we continue to be confident of winning approval for Aorfix(TM) in this important market." | nod | |
11/1/2011 12:42 | happy to see a steady amount of volume though. needs a bit of news soonish to keep it up | webshares | |
11/1/2011 10:41 | morning web, looks most are holding, that's why we are moving up well on low volume ;-) | jab118 | |
11/1/2011 08:41 | its hard to put a price on this share but i would say 3p is a good start. what will the price be if and when it gets fda approval?? who knows. either way i'm holding | webshares |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions